VolitionRx reports Q3 2022 results; cash $16.4M, monthly burn ~$2.3M; new global vet supply deal

VOLITIONRX LTD

Cash at Sep 30: $16.4M; net cash used in operations ~$2.3M/month.
Raised ~$6.4M net from public offering; secured $1.5M non-dilutive from Namur Invest.
Post-quarter: signed global supply agreement for Nu.Q Vet Cancer Test with a pet healthcare market leader; launched via Heska in U.S. and soon Europe.
Appointed DXOCRO for U.S. clinical validation studies of Nu.Q NETs and Cancer tests; pre-submission to FDA anticipated in 2023.
Started lung cancer biomarker study with Hospices Civils de Lyon (ILYAD) to develop national screening program.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VOLITIONRX LTD reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended September 30, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

VOLITIONRX LTD filing history →

Source: SEC EDGAR

accession 0001477932-22-008523

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.